• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Tag Archive for: (AMGN)

Mad Hedge Fund Trader

Ten More Reasons to Buy Amgen

Biotech Letter

In this current coronavirus market, discovering a stock that can survive the pandemic without suffering a major hit is akin to finding the Holy Grail.

This is why I’m on the lookout for undervalued names that offer strong dividends and a stable balance sheet.

In my search, I once again came across the biotechnology pioneer Amgen (AMGN), a 40-year-old company that has continuously proven its critics wrong.

After four decades in the business, this healthcare heavyweight has yet to show any signs of slowing down. If anything, Amgen has been consistent in its efforts to show off its promising pipeline.

In 2020 alone, the company reported at least 39 drug candidates in its pipeline, with practically half already in Phase 3 trials.

As one of the founding fathers of the biotechnology sector, Amgen, which was founded by my UCLA college biochemistry professor, would be remiss to skip on the coronavirus race. If I’d only stuck with him a little longer, I would be filthy rich by now.

In April, the company announced its collaboration with Adaptive Biotechnologies (ADPT) to develop antibodies to be used for COVID-19 treatment.

While the biotechnology giant isn’t the first to jump into the fray, it has an undeniable ace up its sleeve: Amgen is known as one of the leaders in the development of antibody-based treatments. This alone makes it a strong contender. 

Outside its coronavirus work, Amgen has an extensive list of prospects in its pipeline along with a number of workhorse drugs.

However, not everything is as smooth sailing as investors would hope.

Previous blockbusters, rheumatoid arthritis drug Enbrel and chemotherapy medication Neulasta, which comprised 40% of Amgen’s product sales in the first quarter of 2019, failed to move the needle during the same period in 2020. Actually, Neulasta suffered a devastating 40% drop in sales.

Other top performers like multiple myeloma treatment Xgeva and anemia drug Aranesp are having trouble as well, eking out a measly 2% in sales gains in the said period.

As for anemia injection Epogen, the bestselling drug dropped by 29%. Even the sales of hyperparathyroidism medication Cinacalcet slid by 42%.

Overall, this doesn’t sound like an auspicious beginning for Amgen this 2020.

Nonetheless, the company’s robust growth in other areas made up for the laggards.

In fact, Amgen’s total product sales increased by 12%, jumping from $5.3 billion in the first quarter of 2019 to almost $5.9 billion in the same period in 2020.

For instance, sales of osteoporosis treatment Prolia jumped by 10%, pushing the drug in the second spot among the top 10 products in Amgen’s portfolio.

Meanwhile, cholesterol drug Repatha continues to impress, showing off a 62% increase in revenue from $141 million to $229 million.

Even the newer multiple myeloma treatment Kryprolis went up by 19%, while metastatic colorectal cancer injection Vectibix registered a 19% sales gain. Sales for cancer medication Blincyto also went up by 36% year over year to hit $94 million.

Another drug surging forward is kidney treatment Parsabiv, which reported a 39% increase in sales. Newcomer postmenopausal osteoporosis drug Evenity, which was launched in the US market just last year, recorded a respectable $100 million in sales.

In terms of developments that actually pushed the needle for Amgen, the first thing that comes to mind is definitely the acquisition of psoriasis and psoriatic arthritis medication Otezla.

This blockbuster drug, which the company bought for $13.4 billion in cash from the recently acquired Celgene Corporation (CELGN), raked in $479 million in revenues for the first quarter of 2020 alone.

Amgen executives estimate a low double-digit year-over-year sales increase for Otezla up until 2024.

Another exciting development for Amgen is its deal with BeiGene (BGNE), in which the biotechnology pioneer acquired a 20.5% stake in the Chinese company.

Part of this deal is BeiGene’s efforts to commercialize select drugs from Amgen’s oncology lineup to target the expansive Chinese market.

On top of this, the two companies are slated to develop 20 new cancer drugs as well. So far, AMG 510 and tezepelumab are eyed to be launched by 2021.

Amgen is also gearing up to ride the wave of biosimilars, which has a market estimated to surpass $69 billion in the next five years. Due to its lower costs, biosimilars are projected to save consumers roughly $160 billion during the same period.

Perhaps this lucrative opportunity is what made Amgen realize that if they can’t beat them, they might as well join them. That is, the company has already worked towards becoming a major player in the biosimilar space.

In fact, Amgen has started with this plan in 2017 courtesy of the company’s first-ever approved cancer-fighting biosimilar: Mvasi.

So far, Amgen has 10 biosimilars in its current pipeline. Four of which already received FDA approval.

Looking at Amgen’s financial records, it’s safe to say that the company has a strong financial position.

It offers a yield of approximately 2.8% and a payout ratio of over 47%. The dividend coverage ratio is roughly 212%, ensuring a safe dividend and a 5-year growth rate of almost 19%.

Amgen’s profit margin is recorded to be at least 23% in 9 of the recent 10 fiscal years, with growth expected since 1 in 5 cancer patients in the United States uses Amgen medication.

The company’s free cash flow in the first quarter of 2020 rose to $2 billion from the $1.7 billion reported during the same period in 2019.

These quarterly results along with its multitude of growth prospects are proof to Amgen’s capacity to navigate through the decline in other product offerings. The biotechnology company’s numbers in the first quarter of this year demonstrate there’s a good chance it will break through resistance because of its solid sales momentum.

This makes Amgen attractive to long-term biotechnology and healthcare investors. With its strong record, promising pipeline, and decent dividend, the company will be able to sustain its status as a good buy.

Amgen biotechnology

https://www.madhedgefundtrader.com/wp-content/uploads/2019/06/amgen.png 216 462 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-02 09:30:072020-06-02 20:56:04Ten More Reasons to Buy Amgen
Mad Hedge Fund Trader

April 7, 2020

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
April 7, 2020
Fiat Lux

Featured Trade:

(AMGEN THROWS ITS HAT IN THE RING WITH COVID-19)
(AMGN), (ADPT)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-04-07 14:02:432020-04-07 14:35:54April 7, 2020
Mad Hedge Fund Trader

Amgen Throws its Hat in the Ring with Covid-19

Biotech Letter

Another biotech heavyweight, Amgen, has entered the race to find a cure for the deadly coronavirus disease (COVID-19).

Amgen (AMGN) has decided to collaborate with Adaptive Biotechnologies (ADPT) in order to develop a treatment targeting COVID-19. Specifically, the joint effort will rely heavily on Amgen’s immunology expertise combined with Adaptive’s innovative platform used to identify virus-neutralizing antibodies.

The trials will focus on studying the antibodies of individuals who successfully recovered from COVID-19.

Similar to how Biogen (BIIB) and Vir Biotechnology (VIR) handled their collaboration, Amgen and Adaptive also opted to take the plunge even before finalizing all the details of the deal.

Although the urgency of the pandemic is definitely one of the reasons both companies agreed to this setup, another reason could be their history of working together.

Amgen and Adaptive first started collaborating in 2017 when the two companies developed a test for acute lymphoblastic leukemia patients.

In 2019, they expanded their partnership with Amgen utilizing Adaptive’s next-generation sequencing assays for all the blood cancer drugs and even pipeline candidates.

Prior to its partnership with Amgen, Seattle-based Adaptive has been blazing a path in the biotech world. Its biggest claim to fame is its ability to sequence the human immune system.

This is far more challenging than human genome mapping, which only involves 30,000 genes. To sequence the immune system, you would need to look at 100 million genes.

As if that wasn’t challenging enough, Adaptive has also ventured on mapping over 30 billion immune receptors, even owning the data rights to 20 billion of those.

Sensing the potential and the demand from this genetic sequencing system, Microsoft (MSFT) actually offered a collaboration agreement with Adaptive in 2017.

This partnership resulted in a system that can create a universal blood test, which helps doctors read and analyze a patient’s immune system. They will then be able to determine what diseases a person’s body is fighting.

For instance, the body of a cancer patient knows of the threat so its immune system starts fighting the cancer cells. However, this is not immediately known to the doctors, especially without the usual symptoms.

With Adaptive’s system though, the doctors will be able to hack into the immune system of the patient and discover what the body is reacting to. This will allow the doctors to diagnose any disease as early as possible regardless of the appearance of symptoms.

Armed with the information from Adaptive’s test, the doctors will be able to prescribe the right treatments and drugs to boost the patient’s immune system and eventually cure the disease.

Needless to say, Adaptive’s innovative technology would be particularly useful in the fight against COVID-19.

Meanwhile, Amgen seems to be sailing through the economic crisis smoothly.

In fact, this giant biotech even recorded a 1.5% gain in March despite the historic beating suffered by the broader market.

To put things in perspective, the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite Index all lost over 10% of their value last month.

In comparison, Amgen was one of the handful of blue-chip stocks to wrap up March on a positive note.

Several factors contributed to Amgen’s resilience amid the pandemic and economic crisis.

One is the company’s newer drugs in the market such as cholesterol treatment Repatha and postmenopausal drug Prolia. Both recorded a double-digit increase in sales for the first quarter of 2020.

Amgen is also banking on the expansion of its blockbuster psoriasis treatment Otezla, which represents a profitable growth space for the company. The worldwide psoriasis market is projected to reach roughly $46.6 billion by 2022.

Apart from these, Amgen has approximately 40 drugs queued in its pipeline with half already in their Phase 3 trials. Obviously, that’s promising news, especially for long-term investors.

The company has been quite optimistic about its performance this year, estimating a minimum 6.8% increase in annual revenue to fall somewhere between $25 billion and $25.6 billion.

Finally, Amgen has been steadily increasing its dividend every year. Just last year, the company paid a yearly dividend worth $5.80 for each share, showing a 10% jump from 2018.

So far, Amgen has proven itself as one of the stocks immune to the COVID-19 threats and even the widely feared economic crisis.

Since the pandemic isn’t anticipated to peter out in the next months, investors will definitely be on the lookout for high-quality businesses capable of paying solid dividends and can still earn despite the ongoing crisis. Amgen manages to tick off both of these crucial boxes.

Amgen covid-19

 

Amgen covid-19

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-04-07 14:00:072020-05-31 21:09:33Amgen Throws its Hat in the Ring with Covid-19
Mad Hedge Fund Trader

March 5, 2020

Diary, Newsletter, Summary

Global Market Comments
March 5, 2020
Fiat Lux

SPECIAL MARKET BOTTOM ISSUE

Featured Trade:

(FRIDAY, APRIL 17 SAN FRANCISCO STRATEGY LUNCHEON),
(A LEAP PORTFOLIO TO BUY AT THE BOTTOM),
(TEN LONG-TERM BIOTECH & HEALTHCARE LEAPS TO BUY AT THE BOTTOM)
(UNH), (HUM), (AMGN), (BIIB), (JNJ), (PFE), (BMY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-03-05 06:06:242020-03-05 05:19:27March 5, 2020
Mad Hedge Fund Trader

March 5, 2020

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
March 5, 2020
Fiat Lux

SPECIAL MARKET BOTTOM ISSUE

Featured Trade:
(TEN LONG TERM BIOTECH & HEALTH CARE LEAPS TO BUY AT THE BOTTOM)
(UNH), (HUM), (AMGN), (BIIB), (JNJ), (PFE), (BMY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-03-05 06:04:562020-03-05 05:33:12March 5, 2020
Mad Hedge Fund Trader

Ten Long Term Biotech & Healthcare LEAPs to Buy at the Bottom

Biotech Letter, Diary, Newsletter

Joe Biden’s romp over Bernie Sanders in the Tuesday Democratic primary takes the lid off on the entire biotech and healthcare sector. Sanders has promised to dismantle the entire sector by promising Medicare for all and banning private coverage.

Sanders was also about to take a cudgel to drug pricing. While Sanders was leading in the primary, the threats hung over the industry like an 800-pound gorilla.

Yesterday, Sanders went down in flames. You can see this clearly in the price action of Humana (HUM), which rose a ballistic 14.44% yesterday. Similarly, United Health Group (UNH) was up a monster 10.72%.

It is safe to say that the bottom is in for biotech and healthcare stocks.

I am often asked how professional hedge fund traders invest their personal money. They all do the exact same thing. They wait for a market crash like we are seeing now and buy the longest-term LEAPs possible for their favorite names.

The reasons are very simple. The risk of a LEAP is limited. You can’t lose any more than you put in. At the same time, they permit enormous amounts of leverage.

Two years out, the longest maturity available for most LEAPs, allow plenty of time for the world and the markets to get back on an even keel. Recessions, pandemics, hurricanes, oil shocks, interest rate spikes, and political instability all go away within two years and pave the way for dramatic stock market recoveries.

You just put them away and forget about them. Wake me up when it is 2022.

I put together this portfolio using the following parameters. I set the strike prices just short of the all-time highs set two weeks ago. I went for the maximum maturity. I used today’s prices. And of course, I picked the names that have the best long-term outlooks.

If you buy LEAPs at these prices and the stocks all go to new highs, then you should earn an average 229% profit from an average stock price increase of only 11.4%. That is a return 20 times greater than the underlying stock gain. And let’s face it. None of the companies below are going to zero, ever. Now you know why hedge fund traders only employ this strategy.

There is a smarter way to execute this portfolio. Put in throw-away crash bids at levels so low they will only get executed on the next 1,000 point down day in the Dow Average.

You can play around with the strike prices all you want. Going farther out of the money increase your returns, but raises your risk as well. Going closer to the money reduces risk and returns, but the gains are still a multiple of the underlying stock.

Buying when everyone else is throwing up on their shoes is always the best policy. That way your return will rise to ten times the move in the underlying stock.

Amgen (AMGN) - January 21 2022 $235-$240 bull call spread at $3.68 delivers a 172% gain with the stock at $245, up 14% from the current level

Biogen (BIIB) - January 21 2022 $365-$375 bull call spread at $3.89 delivers a 157% gain with the stock at $375, up 14% from the current level

Johnson & Johnson (JNJ) - January 21 2022 $150-$155 bull call spread at $1.63 delivers a 206% gain with the stock at $155, up 8.3% from the current level

Pfizer (PFE) - January 21 2022 $40-$45 bull call spread at $1.05 delivers a 376% gain with the stock at $40.60, up 11.5% from the current level

Bristol Meyers Squibb (BMY) - January 21 2022 $65-$70 bull call spread at $1.50 delivers a 233% gain with the stock at $68, up 11.40% from the current level

 

 

 

 

 

Is He Saying “BUY”?

https://www.madhedgefundtrader.com/wp-content/uploads/2020/03/biden.png 527 791 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-03-05 06:02:212020-03-10 15:15:57Ten Long Term Biotech & Healthcare LEAPs to Buy at the Bottom
Mad Hedge Fund Trader

February 13, 2020

Diary, Newsletter

Global Market Comments
February 13, 2020
Fiat Lux

Featured Trade:

(I HAVE AN OPENING FOR THE MAD HEDGE FUND TRADER CONCIERGE SERVICE),
(MAD HEDGE FUND TRADER CELEBRATES ITS 12-YEAR ANNIVERSARY)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-13 04:06:162020-02-12 19:53:15February 13, 2020
Mad Hedge Fund Trader

February 12, 2020

Diary, Newsletter

Global Market Comments
February 10, 2020
Fiat Lux

Featured Trade:

(LEARN MORE ABOUT ME THAN YOU PROBABLY WANT TO KNOW),
(GOOG), (AMZN), (AMGN)
(WHO SAYS THERE AREN’T ANY GOOD JOBS?),
(TESTIMONIAL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-12 04:08:552020-02-11 17:39:18February 12, 2020
Mad Hedge Fund Trader

Learn More About Me Than You Probably Want to Know

Diary, Newsletter

As you may imagine, the most interesting man in the world is impossible to shop for when it comes to Christmas and birthdays.

So, it was no surprise when I opened a box and found a DNA testing kit from 23 and Me. So, I spit into a small test tube to humor the kids, mailed it off, and forgot about it.

I have long been a keeper of the Thomas family history and legends, so it would be interesting to learn which were true and which were myths.

A month later, what I discovered was amazing.

For a start, I am related to Louis the 16th, the last Bourbon king of France who was beheaded after the 1789 revolution.

I am a direct descendant from Otzi the Iceman who is 5,000 years old and was recently discovered frozen in an Alpine glacier. He currently resides in mummified form in an Italian museum.

Oh, one more. The reason I don’t have any hair on my back is that I carry 346 gene fragments that I inherited directly from a Neanderthal. Yes, I am part caveman, although past girlfriends suspected as much.

There were other conclusions.

I have a higher than average probability of getting prostate cancer, advanced macular degeneration (my mother had it), celiac disease, and melanoma.

The service also offered to introduce me to 1,107 close relatives around the world who I didn’t know, mostly in New York, California, and Florida.

The French connection I already knew about. During the 16th century, my ancestors rebelled against the French kings over the non-payment of taxes and were exiled to Louisiana. Fleeing a malaria epidemic, they moved up the Mississippi River to St. Louis and stayed there for 200 years. When gold was discovered in California in 1849, they joined a wagon train west. We have been here ever since.

I am half Italian and have birth certificates going back to 1800 to prove it. But 23 and Me says that I am only 40.7% Italian (see table below). It turns out that your genes show not only where you came from, but also who invaded your home country since the beginning of time.

In Italy’s case that would include the ancient Greeks, Vikings, Arabs, the Normans, French, Germans, and the Spanish, thus making up my other 9.3%. Your genes also reflect the slaves your ancestors owned, for obvious reasons, as well as many of the servants who may have worked for them.

It gets better.

All modern humans are decended from a single primordial “Eve” who lived in Eastern Africa 180,000 years ago. Of the thousands of homo sapiens who probably lived at that time, the genes of no other human made it into the modern age. We  are all decended from a single “Adam” who lived 275,000 years ago. Obviously, the two never met, debunking some modern conventions.

Around 53,000 years ago, my intrepid ancestors cross the Red Sea to a lush jungle in the Sinai Penninsula probably pursuing abundant game. 53,000 years ago, they moved on the vast grasslands of the Cental Asian Steppes. As the last Ice Age retreated, they moved into the warmer climes of South Europe. We have been there ever since.

23 and Me was founded in 2006 by Anne Wojcicki, wife of Google founder Sergei Brin. It is owned today by her and a few other partners. Its name is based on the fact that humans' entire DNA code is found on 23 chromosomes.

23 and Me and other competitors like Ancestry.com, MyHeritage, and Living DNA have sparked a DNA boom that has led to once unimaged economic and social consequences. DNA promises to be for the 21st century what electricity was to the 20th century. The investment consequences are amazing.

Talk about unintended consequences with a turbocharger.

A common ancestor going back to the early 1800s enabled Sacramento police to capture the Golden State killer. Unsolved for 40 years, it took a week for them to find him after a DNA sample was sent to a DNA database.

Thirty and 40-year cold cases are now being solved on a weekly basis. Long ago kidnapped children are being reunited with parents after decades of separation.

California just froze all executions. That’s because DNA evidence showed that approximately 30% of all capital case convictions were of innocent men. That was enough for me to change my own view on the death penalty. The error rate was just too high. Dozens of men around the country have been freed after new DNA evidence surfaced, some after serving 30 years or more in prison.

23 and Me had some medical advice for me as well. They strongly recommended that I get tested for diabetes and high blood pressure as these maladies are rife among my ancestors. They even name the specific guilty gene and haploid group.

This explains why major technology companies, like Amazon (AMZN) and Apple (AAPL), are pouring billions of dollars into genetic research.

I have long had a personal connection with DNA research. I worked on the team that sequenced the first ever string of DNA at UCLA in 1974. It was groundbreaking work. We obtained our raw DNA from Dr. James Watson of Harvard who, along with Francis Crick, was the first to discover its three-dimensional structure. As for my UCLA professor, Dr. Winston Salser, he went on to found Amgen (AMGN) in 1980 and became a billionaire.

The developments that are taking place today then seemed to us like science fiction that was hundreds of years into the future. To see the paper created by this work, please click here.
 
As research into DNA advances, it is about to pervade every aspect of our lives. Do you have a high probability of getting a disease that costs a million dollars to cure and is counting on getting health insurance? Think again. That may well bring forward single-payer national healthcare for the US, as only the government could absorb that kind of liability.

And if you can only hang on a few years, you might live forever. That’s when DNA-based monoclonal antibodies and gene editing are about to cure all major human diseases. DNA is about to become central to your physical health and your financial health as well.

To learn more about 23 and Me please visit their website here.

Maybe the next time I visit the Versaille Palace outside of Paris, I should ask for a set of keys now that I’m a relative? Unfortunately, it’s much more likely that I’ll get the keys to my Neanderthal ancestor’s cave.

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/23-and-me-3.png 358 283 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-02-12 04:06:272020-02-11 17:39:38Learn More About Me Than You Probably Want to Know
Mad Hedge Fund Trader

December 17, 2019

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
December 17, 2019
Fiat Lux

Featured Trade:

(WHY THE M&A BOOM WILL SPILL INTO 2020),
(BMY), (CELG), (NOVN), (LOXO), (ROG), (ONCE), (MRK), (SAN), (ARQL), (THOR), (AMRN), (GSK), (AMGN), (GILD)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-12-17 04:02:342019-12-17 03:55:07December 17, 2019
Page 18 of 21«‹1617181920›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2026. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top